Results 51 to 60 of about 2,249 (191)

Medical therapy of stricturing Crohn’s disease: what the gut can learn from other organs - a systematic review [PDF]

, 2014
Crohn’s disease (CD) is a chronic remitting and relapsing disease. Fibrostenosing complications such as intestinal strictures, stenosis and ultimately obstruction are some of its most common long-term complications.
Dominik Bettenworth, Florian Rieder
core   +1 more source

Circulating periostin level in asthmatic pregnancy [PDF]

, 2018
K
Bohács, Anikó, Ivancsó, István, Losonczy, György, Müller, Veronika, Rigó, János, Szalay, Balázs, Szilasi, Magdolna Emma, Tamási, Lilla, Toldi, Gergely, Vásárhelyi, Barna   +9 more
core   +5 more sources

Asthma referrals : a key component of asthma management that needs to be addressed [PDF]

, 2017
Peer reviewedPublisher ...
Bergen, David A, Bjermer, Leif, Martinez, Rafael, Price, David   +3 more
core   +1 more source

Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years

Journal of Dermatological Treatment
Background Lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, effectively treats moderate-to-severe atopic dermatitis (AD).Methods Lebrikizumab-treated patients in ADvocate1&2 achieving per-protocol response—IGA (0,1) or EASI 75 ...
Eric Simpson, Tilo Biedermann, Leon Kircik, Raj Chovatiya, Ignasi Figueras, Gaia Gallo, Marta Casillas, Yuxin Ding, Chenjia Xu, Chaoran Hu, Evangeline Pierce, Helena Agell, Christian Vestergaard   +12 more
doaj   +1 more source

Periostin as a novel biomarker for postoperative recurrence of chronic rhinosinitis with nasal polyps [PDF]

, 2018
We previously reported that chronic rhinosinusitis with nasal polyps (CRSwNP) was subdivided into four chronic rhinosinusitis (CRS) subtypes using the JESREC scoring system.
Fujieda Shigeharu, Haruna Shinichi, Haruna Takenori, Hasegawa Masayo, Izuhara Kenji, Kanno Masafumi, Kidoguchi Masanori, Narita Norihiko, Ninomiya Takahiro, Noguchi Emiko, Ohta Shoichiro, Okada Masafumi, Okamoto Masayuki, Okano Mitsuhiro, Ono Junya, Sakashita Masafumi, Sakuma Yasunori, Takabayashi Tetsuji, Tokunaga Takahiro, Yamashita Yukiko, Yoshida Naohiro, Yoshida Takuto, 野口 惠美子   +22 more
core   +2 more sources

Mepolizumab versus placebo for asthma [PDF]

, 2015
Background Mepolizumab is a human monoclonal antibody against interleukin-5 (IL-5), the main cytokine involved in the activation of eosinophils, which in turn causes airway inflammation.
Alvarez-Cuesta, Armentia, Ayars, Ayars, Ayres, Bel, Berger, Blanken, Blanken, Boever, Boulet, Bousquet, Bousquet, Braman, Brown, Bryant, Bryant, Buhl, Buhl, Buhl, Bush, Busse, Busse, Buttner, Caffarelli, Castro, Castro, Chandra, Chervinsky, Clavel, Corren, Corren, Cruz, Cullell-Young, Djukanovic, Ebner, Eckman, El-Nawawy, Fahy, Fahy, Finn, Flood-Page, Flood-Page, Flood-Page, Flood-Page, Frew, Fuhlbrigge, Garcia, Gauvreau, Gauvreau, Gauvreau, Gauvreau, Gevaert, Gibson, Gordon, Greenberg, Gupta, Haldar, Haldar, Haldar, Han, Hanania, Hanania, Hanania, Hill, Hodsman, Holgate, Hoshino, Humbert, Humbert, Humbert, Jacquemin, Jutel, Kandane-Rathnayake, Kang, Kay, Kips, Kon, Kopp, Kopp, Krishnan, Kulus, Lanier, Lanier, Laviolette, Leckie, Leynadier, Lizaso, Masoli, Massanari, Massanari, Mathur, Menzies-Gow, Menzies-Gow, Metzger, Milgrom, Milgrom, Modlin, Moss, Nair, Nair, Nair, Niven, Noga, Noga, Noonan, Oba, Oh, Ohashi, Ohman, Ohta, Ong, Ortega, Ortega, Parker, Patel, Pauli, Pavord, Pavord, Phipps, Piper, Prieto, Pui, Rensen, Rose, Sakamoto, Scheerens, Scheerens, Siergiejko, Silk, Silkoff, Simoes, Singh, Slavin, Soler, Sorkness, Sthoeger, Sugaya, Swanson, Szymaniak, Tanaka, Terr, Vignola, Wark, Wenzel, Wenzel, Wu, Zetterstrom, Zhu, Zielen   +149 more
core   +2 more sources

Group 2 Innate Lymphoid Cells in Respiratory Allergic Inflammation [PDF]

, 2019
Millions of people worldwide are suffering from allergic inflammatory airway disorders. These conditions are regarded as a consequence of multiple imbalanced immune events resulting in an inadequate response with the exact underlying mechanisms still ...
Duerr, Claudia U., Fritz, Jörg H., Helfrich, Sofia, Mindt, Barbara C.   +3 more
core   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis

Pharmaceutics, 2023
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient’s quality of life and requires ongoing management.
Yuliya Lytvyn, Melinda Gooderham
doaj   +1 more source

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal, Emily Moon, Georgios Kallikas   +2 more
wiley   +1 more source